CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Novo Nordisk GlucaGen® +1 moredrug
Likely dose
Novo Nordisk GlucaGen® 0.3 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02081001
NCT02081001Phase 2Completed
CompareCT.gov

Comparison of Pharmacokinetic and Pharmacodynamic Profiles of G-Pump™ (Glucagon Infusion) vs. GlucaGen® Delivered Subcutaneously to Subjects With Type 1 Diabetes (T1DM)

Xeris Pharmaceuticals·interventional·Posted Mar 7, 2014·Updated Apr 6, 2018

In Brief

A Phase 2 clinical trial evaluating Novo Nordisk GlucaGen® and G-Pump™ (glucagon infusion) for Hypoglycemia. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emissary International LLC

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 7, 2014
Enrollment StartMar 1, 2014
Primary CompletionAug 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.3 years ago

Interventions

Novo Nordisk GlucaGen®drug

single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg

G-Pump™ (glucagon infusion)drug

single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg